Kymera Therapeutics (NASDAQ:KYMR) PT Lowered to $52.00

Kymera Therapeutics (NASDAQ:KYMR) had its target price reduced by Oppenheimer from $53.00 to $52.00 in a research report released on Friday, Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

KYMR has been the topic of a number of other research reports. Piper Sandler upped their price objective on Kymera Therapeutics from $39.00 to $56.00 and gave the stock an overweight rating in a report on Tuesday, February 27th. Truist Financial increased their price target on shares of Kymera Therapeutics from $41.00 to $54.00 and gave the company a buy rating in a report on Friday, March 1st. JPMorgan Chase & Co. lifted their price target on shares of Kymera Therapeutics from $34.00 to $47.00 and gave the company an overweight rating in a research report on Friday, February 23rd. Wolfe Research initiated coverage on Kymera Therapeutics in a report on Thursday, February 15th. They issued a peer perform rating on the stock. Finally, Stifel Nicolaus lifted their price objective on Kymera Therapeutics from $35.00 to $55.00 and gave the stock a buy rating in a report on Friday, February 23rd. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average target price of $41.10.

Kymera Therapeutics Stock Performance

Shares of Kymera Therapeutics stock opened at $38.30 on Friday. The firm has a fifty day moving average of $38.42 and a two-hundred day moving average of $29.76. Kymera Therapeutics has a one year low of $9.60 and a one year high of $45.31.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04. Kymera Therapeutics had a negative net margin of 194.67% and a negative return on equity of 31.92%. The firm had revenue of $10.30 million during the quarter, compared to the consensus estimate of $14.24 million. During the same quarter last year, the firm earned ($0.70) earnings per share. The firm’s revenue was up 8.4% compared to the same quarter last year. On average, equities research analysts forecast that Kymera Therapeutics will post -3.15 earnings per share for the current fiscal year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, insider Jared Gollob sold 46,137 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $35.50, for a total transaction of $1,637,863.50. Following the sale, the insider now owns 74,709 shares in the company, valued at approximately $2,652,169.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of the firm’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $42.85, for a total transaction of $1,812,640.70. Following the sale, the insider now owns 4,925,812 shares in the company, valued at $211,071,044.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jared Gollob sold 46,137 shares of the firm’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $35.50, for a total value of $1,637,863.50. Following the sale, the insider now owns 74,709 shares in the company, valued at approximately $2,652,169.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 474,051 shares of company stock worth $19,624,211. 15.82% of the stock is owned by insiders.

Institutional Investors Weigh In On Kymera Therapeutics

Hedge funds have recently made changes to their positions in the business. Massachusetts Financial Services Co. MA boosted its holdings in shares of Kymera Therapeutics by 23.0% during the third quarter. Massachusetts Financial Services Co. MA now owns 463,533 shares of the company’s stock worth $6,443,000 after purchasing an additional 86,585 shares during the last quarter. Dark Forest Capital Management LP raised its position in shares of Kymera Therapeutics by 89.0% in the 3rd quarter. Dark Forest Capital Management LP now owns 36,698 shares of the company’s stock worth $510,000 after buying an additional 17,280 shares during the period. FMR LLC raised its position in shares of Kymera Therapeutics by 3.9% in the 3rd quarter. FMR LLC now owns 870,547 shares of the company’s stock worth $12,101,000 after buying an additional 32,335 shares during the period. Hsbc Holdings PLC purchased a new position in shares of Kymera Therapeutics in the 3rd quarter worth $185,000. Finally, Algert Global LLC raised its position in shares of Kymera Therapeutics by 130.6% in the 3rd quarter. Algert Global LLC now owns 128,532 shares of the company’s stock worth $1,787,000 after buying an additional 72,802 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.